November 5, 2011 -- “China is part of our global strategy and everything China does is related to our global strategy,” says Roche’s Global Head of BD, Dr. Joe McCracken, in an exclusive interview with ChinaBio® Today; Novo Nordisk A/S will innovate to grow in China, rather than using M&A to expand into generics; CNBG will definitely stage an IPO in Hong Kong, though its size is still a mystery; Aslan Pharma of Singapore and Bristol-Myers Squibb partnered to develop a BMS solid tumor oncology drug; US-based Alios BioPharma in-licensed influenza treatment technology from the University of Hong Kong; ImmBio of the UK will co-develop a TB vaccine with Sinopharm Vaccine Institute; the US FDA launched a new IT system to increase tracking of foreign drugs; and Healthgen Biotech published a journal article on its biotech version of human serum albumin, a plasma protein. More details….
Stock Symbols: (SIX: ROG) (NYSE: NVO) (NYSE: BMY)
